NASDAQ:CERS Cerus (CERS) Stock Price, News & Analysis $2.02 -0.06 (-2.88%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$1.97▼$2.1050-Day Range$1.70▼$2.3952-Week Range$1.21▼$2.59Volume694,766 shsAverage Volume1.20 million shsMarket Capitalization$373.48 millionP/E RatioN/ADividend YieldN/APrice Target$3.83 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Cerus alerts: Email Address Cerus MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside89.8% Upside$3.83 Price TargetShort InterestHealthy3.45% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.10Based on 3 Articles This WeekInsider TradingSelling Shares$115,892 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.13) to ($0.07) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.41 out of 5 starsMedical Sector443rd out of 910 stocksSurgical & Medical Instruments Industry53rd out of 95 stocks 3.3 Analyst's Opinion Consensus RatingCerus has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageCerus has received no research coverage in the past 90 days.Read more about Cerus' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.45% of the outstanding shares of Cerus have been sold short.Short Interest Ratio / Days to CoverCerus has a short interest ratio ("days to cover") of 6.9.Change versus previous monthShort interest in Cerus has recently decreased by 0.62%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldCerus does not currently pay a dividend.Dividend GrowthCerus does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CERS. Previous Next 2.3 News and Social Media Coverage News SentimentCerus has a news sentiment score of 0.10. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Cerus this week, compared to 2 articles on an average week.Search Interest3 people have searched for CERS on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cerus insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $115,892.00 in company stock.Percentage Held by InsidersOnly 3.40% of the stock of Cerus is held by insiders.Percentage Held by Institutions78.37% of the stock of Cerus is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Cerus' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Cerus are expected to grow in the coming year, from ($0.13) to ($0.07) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cerus is -11.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cerus is -11.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCerus has a P/B Ratio of 7.48. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Cerus' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad True Gold RepublicChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a population of over 1.4 BILLION is “buying gold like there’s no tomorrow,” according to The New York Times. China, a rising global economic threat, aims to reduce its dependence on the US dollar… . Click here now to get your free 'De-Dollarization' Guide. About Cerus Stock (NASDAQ:CERS)Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was incorporated in 1991 and is headquartered in Concord, California.Read More CERS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CERS Stock News HeadlinesSeptember 6 at 9:12 AM | insidertrades.comCerus Co. (NASDAQ:CERS) CFO Sells $61,879.30 in StockAugust 8, 2024 | insidertrades.comRichard J. Benjamin Sells 21,605 Shares of Cerus Co. (NASDAQ:CERS) StockSeptember 7, 2024 | Porter & Company (Ad)War on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.September 6 at 4:52 AM | finance.yahoo.comInsider Selling: CFO Kevin Green Sells 82,657 Shares of Cerus Corp (CERS)August 29, 2024 | americanbankingnews.comHead to Head Analysis: Cerus (NASDAQ:CERS) and Cochlear (OTCMKTS:CHEOF)August 28, 2024 | americanbankingnews.comCerus (NASDAQ:CERS) versus Drägerwerk AG & Co. KGaA (OTCMKTS:DGWPF) Financial ContrastAugust 28, 2024 | americanbankingnews.comCerus (NASDAQ:CERS) vs. Polarean Imaging (OTCMKTS:PLLWF) Financial ComparisonAugust 28, 2024 | americanbankingnews.comFinancial Survey: Biotricity (OTCMKTS:BTCY) and Cerus (NASDAQ:CERS)September 7, 2024 | Porter & Company (Ad)War on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.August 17, 2024 | ca.finance.yahoo.comCERS Sep 2024 2.000 putAugust 17, 2024 | ca.finance.yahoo.comCERS Sep 2024 2.000 callAugust 5, 2024 | finance.yahoo.comCerus Corporation (NASDAQ:CERS) Just Reported Second-Quarter Earnings And Analysts Are Lifting Their EstimatesAugust 3, 2024 | finance.yahoo.comCerus Second Quarter 2024 Earnings: Beats ExpectationsAugust 2, 2024 | seekingalpha.comCerus Corporation (CERS) Q2 2024 Earnings Call TranscriptAugust 1, 2024 | finance.yahoo.comCerus Corporation Announces Second Quarter 2024 Financial Results and Increases Full-Year 2024 Product Revenue Guidance RangeJuly 31, 2024 | markets.businessinsider.comHere's what Wall Street expects from Cerus's earnings reportJune 21, 2024 | businesswire.comCerus Corporation Announces Symposium and Abstracts at the 38th International Congress of the International Society of Blood TransfusionJune 14, 2024 | businesswire.comCerus Corporation Celebrates World Blood Donor Day 2024See More Headlines Receive CERS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cerus and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/01/2024Today9/07/2024Next Earnings (Estimated)11/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryHealth Care Supplies Current SymbolNASDAQ:CERS CUSIP15708510 CIK1020214 Webwww.cerus.com Phone(925) 288-6000Fax925-288-6001Employees625Year Founded1991Price Target and Rating Average Stock Price Target$3.83 High Stock Price Target$5.00 Low Stock Price Target$2.50 Potential Upside/Downside+89.8%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.17) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-37,490,000.00 Net Margins-14.15% Pretax Margin-14.10% Return on Equity-44.27% Return on Assets-11.54% Debt Debt-to-Equity Ratio1.29 Current Ratio2.51 Quick Ratio1.83 Sales & Book Value Annual Sales$169.98 million Price / Sales2.20 Cash FlowN/A Price / Cash FlowN/A Book Value$0.27 per share Price / Book7.48Miscellaneous Outstanding Shares184,890,000Free Float178,604,000Market Cap$373.48 million OptionableOptionable Beta1.19 Social Links Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMr. William M. Greenman (Age 57)President, CEO & Director Comp: $1.04MMr. Kevin D. Green (Age 52)VP of Finance & CFO Comp: $607.53kMr. Vivek K. Jayaraman (Age 49)Chief Operating Officer Comp: $696.68kMs. Chrystal Jensen (Age 53)Chief Legal Officer & General Counsel Comp: $571.49kDr. Richard J. Benjamin MBChB (Age 64)Ph.D., Chief Medical Officer Comp: $603.68kDr. Laurence M. Corash M.D. (Age 80)Co-Founder & Chief Scientific Officer Comp: $697.77kMs. Lori L. RollVP of Administration & Corporate SecretaryMr. Matthew M. NotarianniSenior Director of Investor RelationsLainie CortenVice President of Global MarketingMs. Alicia GoodmanChief Human Resources OfficerMore ExecutivesKey CompetitorsInovio PharmaceuticalsNASDAQ:INOCardiovascular SystemsNASDAQ:CSIISTAAR SurgicalNASDAQ:STAAAtrionNASDAQ:ATRIAnika TherapeuticsNASDAQ:ANIKView All CompetitorsInsiders & InstitutionsKevin Dennis GreenSold 28,385 sharesTotal: $61,879.30 ($2.18/share)Algert Global LLCBought 55,086 shares on 8/16/2024Ownership: 0.030%AQR Capital Management LLCBought 195,112 shares on 8/15/2024Ownership: 0.117%The Manufacturers Life Insurance Company Bought 7,209 shares on 8/15/2024Ownership: 0.040%Marshall Wace LLPSold 162,913 shares on 8/14/2024Ownership: 0.021%View All Insider TransactionsView All Institutional Transactions CERS Stock Analysis - Frequently Asked Questions How have CERS shares performed this year? Cerus' stock was trading at $2.16 at the start of the year. Since then, CERS shares have decreased by 6.5% and is now trading at $2.02. View the best growth stocks for 2024 here. How were Cerus' earnings last quarter? Cerus Co. (NASDAQ:CERS) released its earnings results on Thursday, August, 1st. The biotechnology company reported ($0.03) EPS for the quarter, topping analysts' consensus estimates of ($0.04) by $0.01. The biotechnology company had revenue of $45.08 million for the quarter, compared to analysts' expectations of $42.50 million. Cerus had a negative net margin of 14.15% and a negative trailing twelve-month return on equity of 44.27%. What is William M. (Obi) Greenman's approval rating as Cerus' CEO? 15 employees have rated Cerus Chief Executive Officer William M. (Obi) Greenman on Glassdoor.com. William M. (Obi) Greenman has an approval rating of 35% among the company's employees. This puts William M. (Obi) Greenman in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. Who are Cerus' major shareholders? Top institutional shareholders of Cerus include ARK Investment Management LLC (10.76%), Sumitomo Mitsui Trust Holdings Inc. (4.06%), Hood River Capital Management LLC (0.79%) and Assenagon Asset Management S.A. (0.64%). Insiders that own company stock include William Mariner Greenman, Vivek K Jayaraman, Kevin Dennis Green, Chrystal Jensen, Carol Moore, Richard J Benjamin, Chrystal Menard, Daniel N Swisher Jr, Ann Lucena, Hua Shan, Gail Schulze and Laurence M Corash. View institutional ownership trends. How do I buy shares of Cerus? Shares of CERS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Cerus own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cerus investors own include Rite Aid (RAD), SCYNEXIS (SCYX), Alibaba Group (BABA), Inovio Pharmaceuticals (INO), OPKO Health (OPK), Pfizer (PFE) and Immunomedics (IMMU). This page (NASDAQ:CERS) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cerus Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cerus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CERS Stock Alerts